Florida is currently home to 3831 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Recruiting
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: D&H Cancer Research Center, Margate, Florida
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840735, Brooksville, Florida
Conditions: Chronic Obstructive Pulmonary Disease
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Recruiting
This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
03/11/2025
Locations: Baptist MD Anderson Cancer Center, Jacksonville, Florida
Conditions: Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Gastroschisis Outcomes of Delivery (GOOD) Study
Recruiting
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of South Florida & Tampa General Hospital, Tampa, Florida
Conditions: Gastroschisis
University of Central Florida CereBank
Recruiting
Millions of persons are affected by brain diseases. The CereBank will be used to support research studies aimed at improving the diagnosis and treatment of brain diseases. Brain diseases can be inherited; developed due to diseases or aging; or can be due to trauma. The Central Florida does not have a brain biobank to meet the needs of research. Therefore, it is necessary for the University of Central Florida to establish a brain biobank.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of Central Florida, Orlando, Florida
Conditions: Biospecimen Donation, Brain Injury, Brain Diseases
A Varegacestat Hepatic Impairment Study
Recruiting
This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
03/10/2025
Locations: Orlando Clinical Research Center, Orlando, Florida
Conditions: Healthy Volunteer, Hepatic Impairment (HI)
Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease
Recruiting
The purpose of this clinical trial is to determine the impact of a home-based pulmonary rehabilitation program with health coaching on patient-reported respiratory-related quality of life and physical activity, as compared to usual care in patients with fibrotic interstitial lung disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Lung Fibrosis, Lung Interstitial Disease
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
Gender:
ALL
Ages:
Between 12 years and 55 years
Trial Updated:
03/10/2025
Locations: Quotient Sciences Sea View, Miami, Florida
Conditions: Sickle Cell Disease
Precise Robotically IMplanted Brain-Computer InterfacE
Recruiting
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/10/2025
Locations: University of Miami, Miami, Florida
Conditions: Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Quadriplegia/Tetraplegia, Tetraplegic; Paralysis